よむ、つかう、まなぶ。
【参考資料２－３】抗微生物薬適正使用の手引き 第四版（案）薬剤耐性菌感染症の抗菌薬適正使用編 (53 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_64503.html |
| 出典情報 | 厚生科学審議会 感染症部会（第99回 10／21）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
抗微生物薬適正使用の手引き
第四版
薬剤耐性菌感染症の抗菌薬適正使用編
1
2
3
112. Haręża DA, et al. Clinical outcomes and emergence of resistance of Pseudomonas
aeruginosa infections treated with ceftolozane-tazobactam versus ceftazidimeavibactam. Antimicrob Agents Chemother. 2024. 68(10):e0090724.
4
5
6
113. Almangour TA, et al. Ceftolozane-Tazobactam Versus Ceftazidime-Avibactam for the
Treatment of Infections Caused by Multidrug-Resistant Pseudomonas aeruginosa: a
Multicenter Cohort Study. Antimicrob Agents Chemother. 2023. 67(8):e0040523.
7
8
9
114. Shah S, et al. Rates of Resistance to Ceftazidime-Avibactam and CeftolozaneTazobactam Among Patients Treated for Multidrug-Resistant Pseudomonas aeruginosa
Bacteremia or Pneumonia. Clin Infect Dis. 2025. 80(1):24-28.
10
11
12
13
115. Lodise TP, et al. Comparative evaluation of early treatment with ceftolozane/tazobactam
versus ceftazidime/avibactam for non-COVID-19 patients with pneumonia due to
multidrug-resistant Pseudomonas aeruginosa. J Antimicrob Chemother. 2024.
79(11):2954-2964.
14
116. 西村翔. 誰も教えてくれないザバクサの使いドコロ. J-IDEO. 2019. 3(4):82
15
16
17
117. Shields RK, et al. In vitro activity of cefiderocol against Pseudomonas aeruginosa
demonstrating evolved resistance to novel β-lactam/β-lactamase inhibitors. JAC
Antimicrob Resist. 2023. 5(5):dlad107.
18
19
20
21
118. Bassetti M, et al. Efficacy and safety of cefiderocol or best available therapy for the
treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria
(CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive,
phase 3 trial. Lancet Infect Dis. 2021. 21(2):226-240.
22
23
24
25
119. Hart DE, et al. C/T Alliance to deliver Real-world Evidence (CARE). A Multicenter
Evaluation of Ceftolozane/Tazobactam Treatment Outcomes in Immunocompromised
Patients With Multidrug-Resistant Pseudomonas aeruginosa Infections. Open Forum
Infect Dis. 2021. 8(3):ofab089.
26
27
28
120. Timsit JF, et al. Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamaseProducing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized
Studies. Clin Infect Dis. 2022. 75(6):1081-1084.
29
30
31
32
121. Gill CM, et al. Elevated MICs of Susceptible Antipseudomonal Cephalosporins in NonCarbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa:
Implications for Dose Optimization. Antimicrob Agents Chemother. 2021.
65(11):e0120421.
33
34
122. Hubert D, et al. Continuous versus intermittent infusions of ceftazidime for treating
exacerbation of cystic fibrosis. Antimicrob Agents Chemother. 2009. 53(9):3650-6.
35
36
37
123. Bauer KA, et al. Extended-infusion cefepime reduces mortality in patients with
Pseudomonas aeruginosa infections. Antimicrob Agents Chemother. 2013. 57(7):29072912.
38
39
40
124. Lodise TP, Jr., et al. Piperacillin-tazobactam for Pseudomonas aeruginosa infection:
clinical implications of an extended-infusion dosing strategy. Clin Infect Dis. 2007.
44(3):357-363.
41
42
43
44
45
46
125. Hong LT, et al. International consensus recommendations for the use of prolongedinfusion β-lactam antibiotics: Endorsed by the American College of Clinical Pharmacy,
British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European
Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of
America, Society of Critical Care Medicine, and Society of Infectious Diseases
Pharmacists. Pharmacotherapy. 2023. 43(8):740-777.
53
第四版
薬剤耐性菌感染症の抗菌薬適正使用編
1
2
3
112. Haręża DA, et al. Clinical outcomes and emergence of resistance of Pseudomonas
aeruginosa infections treated with ceftolozane-tazobactam versus ceftazidimeavibactam. Antimicrob Agents Chemother. 2024. 68(10):e0090724.
4
5
6
113. Almangour TA, et al. Ceftolozane-Tazobactam Versus Ceftazidime-Avibactam for the
Treatment of Infections Caused by Multidrug-Resistant Pseudomonas aeruginosa: a
Multicenter Cohort Study. Antimicrob Agents Chemother. 2023. 67(8):e0040523.
7
8
9
114. Shah S, et al. Rates of Resistance to Ceftazidime-Avibactam and CeftolozaneTazobactam Among Patients Treated for Multidrug-Resistant Pseudomonas aeruginosa
Bacteremia or Pneumonia. Clin Infect Dis. 2025. 80(1):24-28.
10
11
12
13
115. Lodise TP, et al. Comparative evaluation of early treatment with ceftolozane/tazobactam
versus ceftazidime/avibactam for non-COVID-19 patients with pneumonia due to
multidrug-resistant Pseudomonas aeruginosa. J Antimicrob Chemother. 2024.
79(11):2954-2964.
14
116. 西村翔. 誰も教えてくれないザバクサの使いドコロ. J-IDEO. 2019. 3(4):82
15
16
17
117. Shields RK, et al. In vitro activity of cefiderocol against Pseudomonas aeruginosa
demonstrating evolved resistance to novel β-lactam/β-lactamase inhibitors. JAC
Antimicrob Resist. 2023. 5(5):dlad107.
18
19
20
21
118. Bassetti M, et al. Efficacy and safety of cefiderocol or best available therapy for the
treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria
(CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive,
phase 3 trial. Lancet Infect Dis. 2021. 21(2):226-240.
22
23
24
25
119. Hart DE, et al. C/T Alliance to deliver Real-world Evidence (CARE). A Multicenter
Evaluation of Ceftolozane/Tazobactam Treatment Outcomes in Immunocompromised
Patients With Multidrug-Resistant Pseudomonas aeruginosa Infections. Open Forum
Infect Dis. 2021. 8(3):ofab089.
26
27
28
120. Timsit JF, et al. Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamaseProducing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized
Studies. Clin Infect Dis. 2022. 75(6):1081-1084.
29
30
31
32
121. Gill CM, et al. Elevated MICs of Susceptible Antipseudomonal Cephalosporins in NonCarbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa:
Implications for Dose Optimization. Antimicrob Agents Chemother. 2021.
65(11):e0120421.
33
34
122. Hubert D, et al. Continuous versus intermittent infusions of ceftazidime for treating
exacerbation of cystic fibrosis. Antimicrob Agents Chemother. 2009. 53(9):3650-6.
35
36
37
123. Bauer KA, et al. Extended-infusion cefepime reduces mortality in patients with
Pseudomonas aeruginosa infections. Antimicrob Agents Chemother. 2013. 57(7):29072912.
38
39
40
124. Lodise TP, Jr., et al. Piperacillin-tazobactam for Pseudomonas aeruginosa infection:
clinical implications of an extended-infusion dosing strategy. Clin Infect Dis. 2007.
44(3):357-363.
41
42
43
44
45
46
125. Hong LT, et al. International consensus recommendations for the use of prolongedinfusion β-lactam antibiotics: Endorsed by the American College of Clinical Pharmacy,
British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European
Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of
America, Society of Critical Care Medicine, and Society of Infectious Diseases
Pharmacists. Pharmacotherapy. 2023. 43(8):740-777.
53